1. Acute changes in both infarcted and noninfarcted post-STEMI (ST-segment elevation acute MI) can predict long-term major adverse cardiac events (MACE).
2. High T1 (>1250 ms) in the noninfarcted post-STEMI was associated with lower left ventricular ejection fraction (LVEF) and higher NT-pro-BNP levels at 6 months, as well as a 2.5-fold increased risk of MACE.
3. Lower T1 (<1300 ms) in the infarcted post-STEMI was associated with increased MACE.
The article is generally reliable and trustworthy, as it is based on a comprehensive study that included blood biomarkers and cardiac magnetic resonance imaging (CMR). The study also had a long follow up period for major adverse cardiac events (MACE), which allowed for accurate assessment of the prognostic value of acute changes in both infarcted and noninfarcted post-STEMI. The authors also provide evidence to support their claims, such as the association between high T1 (>1250 ms) in the noninfarcted post-STEMI with lower LVEF and higher NT-proBNP levels at 6 months, as well as a 2.5 fold increased risk of MACE. Furthermore, they provide evidence that lower T1 (<1300 ms) in the infarcted post-STEMI was associated with increased MACE.
However, there are some potential biases that should be noted when assessing this article's trustworthiness and reliability. For example, the study only included patients who underwent primary percutaneous coronary intervention (PPCI), which may limit its generalizability to other populations or settings where PPCI is not available or used less frequently. Additionally, while the authors note that both noninfarct and infarct T1 were independent predictors of MACE, they do not explore any possible counterarguments or alternative explanations for their findings. Finally, while the authors note that their insights may provide new opportunities for treatment and risk stratification in STEMI, they do not discuss any potential risks associated with these treatments or strategies.